mPATH, a digital health company dedicated to improving cancer screening, raised $ 3 million in funding. The round consisted of a $2M led by a Small Business Technology Grant from the National Cancer Institute (NCI) and a $1M equity investment led by Oncology Ventures.
The company aims to employ the raised funds to accelerate growth and outreach, which means more screening and preventive health modules can be added.
Read also – [Funding news] Brazil-based Agrolend Secures $ 53m in Series C Round Funding
The NCI grant received by the company in July 2024 will help with the commercialization of the mPATH cancer screening program. This award will, of course include additional development, rigorous clinical testing of mPATH’s program, as well as an opportunity for its gradual advancement in this critical space.
With mPATH Health, led by Dr David Miller, a digital health company is innovating preventive cancer screening with automation and the power of Behavioural science. It empowers those individuals to put health first through the use of technology and personal outreach, thereby regularly enabling screening for early discovery of cancer.
About mPATH
mPATH is a B2B software-as-a-service company that improves healthcare organization’s bottom line with an automated platform that closes preventive care gaps. It is a low-cost, cloud-based program that identifies individuals who are overdue for routine screening tests, provides personalized education, and connects patients with needed care.
